These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 28779211)
1. The effect of interleukin-22 treatment on autoimmune diabetes in the NOD mouse. Borg DJ; Wang R; Murray L; Tong H; Steptoe RJ; McGuckin MA; Hasnain SZ Diabetologia; 2017 Nov; 60(11):2256-2261. PubMed ID: 28779211 [TBL] [Abstract][Full Text] [Related]
2. Suppression of insulitis in non-obese diabetic (NOD) mice by oral insulin administration is associated with selective expression of interleukin-4 and -10, transforming growth factor-beta, and prostaglandin-E. Hancock WW; Polanski M; Zhang J; Blogg N; Weiner HL Am J Pathol; 1995 Nov; 147(5):1193-9. PubMed ID: 7485382 [TBL] [Abstract][Full Text] [Related]
3. Transgenic expression of IL-10 in pancreatic islet A cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice. Moritani M; Yoshimoto K; Tashiro F; Hashimoto C; Miyazaki J; Ii S; Kudo E; Iwahana H; Hayashi Y; Sano T Int Immunol; 1994 Dec; 6(12):1927-36. PubMed ID: 7696210 [TBL] [Abstract][Full Text] [Related]
4. MFP14, a multifunctional emerging protein with immunomodulatory properties, prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Panerai AE; Nicoletti F; Sacedote P; Arvidsson L; Conget I; Gomis R; Bartorelli A; Sandler S Diabetologia; 2001 Jul; 44(7):839-47. PubMed ID: 11508268 [TBL] [Abstract][Full Text] [Related]
5. [Oral administration of insulin inhibits islet beta cell apoptosis and prevents diabetes in NOD mice]. Jiang TJ; Zhou ZG Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Aug; 32(4):615-9. PubMed ID: 17767052 [TBL] [Abstract][Full Text] [Related]
6. Disease resistant, NOD-related strains reveal checkpoints of immunoregulation in the pancreas. Rothe H; Ito Y; Kolb H J Mol Med (Berl); 2001 May; 79(4):190-7. PubMed ID: 11409710 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models. McGuire HM; Walters S; Vogelzang A; Lee CM; Webster KE; Sprent J; Christ D; Grey S; King C Diabetes; 2011 Mar; 60(3):867-75. PubMed ID: 21357471 [TBL] [Abstract][Full Text] [Related]
8. Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese diabetic mice. Shapiro AM; Suarez-Pinzon WL; Power R; Rabinovitch A Diabetologia; 2002 Feb; 45(2):224-30. PubMed ID: 11935154 [TBL] [Abstract][Full Text] [Related]
9. Protective effects of combined intervention with adenovirus vector mediated IL-10 and IGF-1 genes on endogenous islet β cells in nonobese diabetes mice with onset of type 1 diabetes mellitus. Zhang L; Chen Y; Li C; Lin X; Cheng X; Li T PLoS One; 2014; 9(3):e92616. PubMed ID: 24663217 [TBL] [Abstract][Full Text] [Related]
10. Local production of human IL-6 promotes insulitis but retards the onset of insulin-dependent diabetes mellitus in non-obese diabetic mice. DiCosmo BF; Picarella D; Flavell RA Int Immunol; 1994 Dec; 6(12):1829-37. PubMed ID: 7696203 [TBL] [Abstract][Full Text] [Related]
11. Metabolically inactive insulin analogue does not prevent autoimmune diabetes in NOD mice. Grönholm J; Pagni PP; Pham MN; Gibson CB; Macomber PF; Vela JL; von Herrath M; Lenardo MJ Diabetologia; 2017 Aug; 60(8):1475-1482. PubMed ID: 28455654 [TBL] [Abstract][Full Text] [Related]
12. Administration of IL-4 prevents autoimmune diabetes but enhances pancreatic insulitis in NOD mice. Tominaga Y; Nagata M; Yasuda H; Okamoto N; Arisawa K; Moriyama H; Miki M; Yokono K; Kasuga M Clin Immunol Immunopathol; 1998 Feb; 86(2):209-18. PubMed ID: 9473384 [TBL] [Abstract][Full Text] [Related]
13. Antidiabetic and Immunoregulatory Activities of Extract of Lin CH; Kuo YH; Shih CC Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373070 [TBL] [Abstract][Full Text] [Related]
14. Interleukin-15 plays an essential role in the pathogenesis of autoimmune diabetes in the NOD mouse. Bobbala D; Chen XL; Leblanc C; Mayhue M; Stankova J; Tanaka T; Chen YG; Ilangumaran S; Ramanathan S Diabetologia; 2012 Nov; 55(11):3010-20. PubMed ID: 22890824 [TBL] [Abstract][Full Text] [Related]
15. Pancreatic expression of B7 co-stimulatory molecules in the non-obese diabetic mouse. Stephens LA; Kay TW Int Immunol; 1995 Dec; 7(12):1885-95. PubMed ID: 8746558 [TBL] [Abstract][Full Text] [Related]
16. Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse. Sreenan S; Pick AJ; Levisetti M; Baldwin AC; Pugh W; Polonsky KS Diabetes; 1999 May; 48(5):989-96. PubMed ID: 10331402 [TBL] [Abstract][Full Text] [Related]
17. Both CD4+ and CD8+ T-cells in syngeneic islet grafts in NOD mice produce interferon-gamma during beta-cell destruction. Suarez-Pinzon W; Rajotte RV; Mosmann TR; Rabinovitch A Diabetes; 1996 Oct; 45(10):1350-7. PubMed ID: 8826970 [TBL] [Abstract][Full Text] [Related]
18. Oral probiotic administration induces interleukin-10 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Calcinaro F; Dionisi S; Marinaro M; Candeloro P; Bonato V; Marzotti S; Corneli RB; Ferretti E; Gulino A; Grasso F; De Simone C; Di Mario U; Falorni A; Boirivant M; Dotta F Diabetologia; 2005 Aug; 48(8):1565-75. PubMed ID: 15986236 [TBL] [Abstract][Full Text] [Related]
19. Double deficiency in IL-17 and IFN-γ signalling significantly suppresses the development of diabetes in the NOD mouse. Kuriya G; Uchida T; Akazawa S; Kobayashi M; Nakamura K; Satoh T; Horie I; Kawasaki E; Yamasaki H; Yu L; Iwakura Y; Sasaki H; Nagayama Y; Kawakami A; Abiru N Diabetologia; 2013 Aug; 56(8):1773-80. PubMed ID: 23699989 [TBL] [Abstract][Full Text] [Related]
20. Effects of interleukin-12 in vitro on pancreatic islets isolated from normal rodents and from non-obese diabetic mice. Sternesjö J; Sandler S J Endocrinol; 1998 Jul; 158(1):69-75. PubMed ID: 9713328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]